320 related articles for article (PubMed ID: 8531089)
1. Growth inhibitory effects on human colon adenocarcinoma-derived Caco-2 cells and calcemic potential of 1 alpha,25-dihydroxyvitamin D3 analogs: structure-function relationships.
Bischof MG; Redlich K; Schiller C; Chirayath MV; Uskokovic M; Peterlik M; Cross HS
J Pharmacol Exp Ther; 1995 Dec; 275(3):1254-60. PubMed ID: 8531089
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3.
Shabahang M; Buras RR; Davoodi F; Schumaker LM; Nauta RJ; Uskokovic MR; Brenner RV; Evans SR
Cancer Res; 1994 Aug; 54(15):4057-64. PubMed ID: 8033137
[TBL] [Abstract][Full Text] [Related]
3. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
4. 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3 and 1alpha,25-dihydroxy-16-ene-23-yne-20-epi-vitamin D3: analogs of 1alpha,25-dihydroxyvitamin D3 that resist metabolism through the C-24 oxidation pathway are metabolized through the C-3 epimerization pathway.
Reddy GS; Rao DS; Siu-Caldera ML; Astecker N; Weiskopf A; Vouros P; Sasso GJ; Manchand PS; Uskokovic MR
Arch Biochem Biophys; 2000 Nov; 383(2):197-205. PubMed ID: 11185554
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog.
Aparna R; Subhashini J; Roy KR; Reddy GS; Robinson M; Uskokovic MR; Venkateswara Reddy G; Reddanna P
J Cell Biochem; 2008 Aug; 104(5):1832-42. PubMed ID: 18348265
[TBL] [Abstract][Full Text] [Related]
6. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
7. Biological effects of 1alpha-hydroxy- and 1beta-(hydroxymethyl)-vitamin D compounds relevant for potential colorectal cancer therapy.
Hofer H; Ho Gm; Peterlik M; Uskokovic MR; Lee JK; White MC; Posner GH; Cross HS
J Pharmacol Exp Ther; 1999 Nov; 291(2):450-5. PubMed ID: 10525058
[TBL] [Abstract][Full Text] [Related]
8. Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues.
Norman AW; Sergeev IN; Bishop JE; Okamura WH
Cancer Res; 1993 Sep; 53(17):3935-42. PubMed ID: 8395333
[TBL] [Abstract][Full Text] [Related]
9. Structure-function studies on analogues of 1 alpha,25-dihydroxyvitamin D3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption.
Norman AW; Zhou JY; Henry HL; Uskokovic MR; Koeffler HP
Cancer Res; 1990 Nov; 50(21):6857-64. PubMed ID: 2208153
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition of human colon adenocarcinoma-derived Caco-2 cells by 1,25-dihydroxyvitamin D3 and two synthetic analogs: relation to in vitro hypercalcemic potential.
Cross HS; Farsoudi KH; Peterlik M
Naunyn Schmiedebergs Arch Pharmacol; 1993 Jan; 347(1):105-10. PubMed ID: 8446178
[TBL] [Abstract][Full Text] [Related]
11. 1 alpha,25-(OH)2-vitamin D3 analogs with minimal in vivo calcemic activity can stimulate significant transepithelial calcium transport and mRNA expression in vitro.
Fleet JC; Bradley J; Reddy GS; Ray R; Wood RJ
Arch Biochem Biophys; 1996 May; 329(2):228-34. PubMed ID: 8638956
[TBL] [Abstract][Full Text] [Related]
12. Biologic activity of dihydroxylated 19-nor-(pre)vitamin D3.
Bouillon R; Sarandeses LA; Allewaert K; Zhao J; Mascareñas JL; Mouriño A; Vrielynck S; de Clercq P; Vandewalle M
J Bone Miner Res; 1993 Aug; 8(8):1009-15. PubMed ID: 8213251
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibitory effects of 1,25-dihydroxyvitamin D3 and its synthetic analogue, 1alpha,25-dihydroxy-16-ene-23yne-26,27-hexafluoro-19-nor-cholecalcifero l (Ro 25-6760), on a human colon cancer xenograft.
Evans SR; Schwartz AM; Shchepotin EI; Uskokovic M; Shchepotin IB
Clin Cancer Res; 1998 Nov; 4(11):2869-76. PubMed ID: 9829754
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D analogs with low affinity for the vitamin D binding protein: enhanced in vitro and decreased in vivo activity.
Bouillon R; Allewaert K; Xiang DZ; Tan BK; van Baelen H
J Bone Miner Res; 1991 Oct; 6(10):1051-7. PubMed ID: 1796753
[TBL] [Abstract][Full Text] [Related]
15. 1,25-Dihydroxyvitamin D3 analog structure-function assessment of the rapid stimulation of intestinal calcium absorption (transcaltachia).
Zhou LX; Nemere I; Norman AW
J Bone Miner Res; 1992 Apr; 7(4):457-63. PubMed ID: 1319106
[TBL] [Abstract][Full Text] [Related]
16. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
Hisatake J; Kubota T; Hisatake Y; Uskokovic M; Tomoyasu S; Koeffler HP
Cancer Res; 1999 Aug; 59(16):4023-9. PubMed ID: 10463602
[TBL] [Abstract][Full Text] [Related]
17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
18. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice.
Zhou JY; Norman AW; Chen DL; Sun GW; Uskokovic M; Koeffler HP
Proc Natl Acad Sci U S A; 1990 May; 87(10):3929-32. PubMed ID: 2339131
[TBL] [Abstract][Full Text] [Related]
19. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo.
Schwartz GG; Hill CC; Oeler TA; Becich MJ; Bahnson RR
Urology; 1995 Sep; 46(3):365-9. PubMed ID: 7660511
[TBL] [Abstract][Full Text] [Related]
20. Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo.
Vegesna V; O'Kelly J; Said J; Uskokovic M; Binderup L; Koeffle HP
Anticancer Res; 2003; 23(1A):283-9. PubMed ID: 12680225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
